Evidence map›Paper›PMID 38027240›Full record

ArticleCancer management and research2023

Characteristics of Real-World Patients with High-Risk

Pietro Quaglino, Paolo A Ascierto, Francesca Consoli, Paola Queirolo, Francesco Spagnolo, Maria Francesca Morelli, Rossana Berardi, Vanna Chiarion-Sileni, Marco Tucci, Teresa Troiani and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 16 institutions in 1 country.

Pietro QuaglinoDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
Paolo A AsciertoDepartment of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Francesca ConsoliDepartment of Oncology, ASST Spedali Civili, Brescia, Italy.
Paola QueiroloOncology Division, Policlinico San Martino IRCCS, Genova, Italy, and Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Francesco SpagnoloSkin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Maria Francesca MorelliDepartment of Oncology and Dermatological Oncology, Istituto Dermopatico dell'Immacola, Rome, Italy.
Rossana BerardiUniversità Politecnica delle Marche - Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy.
Vanna Chiarion-SileniMelanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Marco TucciMedical Oncology Unit, Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Bari, Italy.
Teresa TroianiFaculty of Medicine, Second University of Naples, Naples, Italy.
Barbara MelottiMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Ernesto RossiMedical Oncology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
Mario MandalaDivision of Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy, and University of Perugia, Perugia, Italy.
Gaetana RinaldiUOC Oncologia Medica Aoup Paolo Giaccone, Palermo, Italy.
Ilaria Gioia MarconNovartis Farma S.p.A, Milan, Italy.
Matteo PizzutiNovartis Farma S.p.A, Milan, Italy.
Michele Del VecchioUnit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Novartis (Italy) · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITAzienda USL di Bologna · ITEuropean Institute of Oncology · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Dermopatico dell'Immacolata · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITIstituto Oncologico Veneto · ITMarche Polytechnic University · ITOspedale Policlinico San Martino · ITUniversity of Bari Aldo Moro · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Perugia · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Real-world data from patients with Patients and Methods: Eligible patients had completely resected cutaneous melanoma with confirmed Results: A total of 557 patients received dabrafenib plus trametinib through the MAP (stage III resected disease at inclusion, 554). Median age was 54.0 years, and 40.2% of patients were female. The proportion of all treated patients who required a dose reduction was low (10.8%) as was the proportion of patients who discontinued treatment (13.5%). The main reason for treatment discontinuation was adverse events (36.0%). Conclusion: New treatments, including BRAF-targeted therapies and immunotherapy, have transformed the natural history of melanoma. This is the largest study to date describing patients treated with dabrafenib plus trametinib in routine clinical practice in Italy between 2018 and 2019. Results highlight the characteristics of the patients treated and their journey, as well as the tolerable safety profile of dabrafenib plus trametinib in a real-world patient population.

Indexed as

BRAF mutationdabrafenibmanaged access programmelanomareal-worldtrametinib

Identifiers

PMID38027240
PMCPMC10649847
OpenAlexW4388566415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.